ABOUT ABBVIE IN NEUROSCIENCE
At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie's Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders, including Alzheimer's disease, bipolar disorder and depression, major depressive disorder, migraine, multiple sclerosis, Parkinson's disease, spinal cord injuries, post-stroke spasticity, schizophrenia, stroke and others.

Movement disorders are chronic and progressive neurological conditions impacting the body’s ability to control movement1. At AbbVie Neuroscience, we harness science and our rich experience to advance our understanding of movement disorders. Together with patients, healthcare professionals, care partners and the movement disorder community, we work to increase education and awareness. We are unwavering in our commitment to helping people with movement disorders regain their independence and empowering them to live life on their own terms. For more information, please visit www.abbvie.com.

1. U.S. National Library of Medicine MedlinePlus. Movement Disorders. https://medlineplus.gov/movementdisorders.html. Accessed: September 2021.

Access AbbVie's exhibit materials from the 2021 Annual Assembly.